JP2016514713A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514713A5
JP2016514713A5 JP2016503549A JP2016503549A JP2016514713A5 JP 2016514713 A5 JP2016514713 A5 JP 2016514713A5 JP 2016503549 A JP2016503549 A JP 2016503549A JP 2016503549 A JP2016503549 A JP 2016503549A JP 2016514713 A5 JP2016514713 A5 JP 2016514713A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
polypeptide
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2014/000015 external-priority patent/WO2014146663A1/en
Publication of JP2016514713A publication Critical patent/JP2016514713A/ja
Publication of JP2016514713A5 publication Critical patent/JP2016514713A5/ja
Priority to JP2019052389A priority Critical patent/JP7510142B2/ja
Pending legal-status Critical Current

Links

JP2016503549A 2013-03-18 2014-03-17 クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン Pending JP2016514713A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019052389A JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300155 2013-03-18
DKPA201300155 2013-03-18
DKPA201300684 2013-12-11
DKPA201300684 2013-12-11
PCT/DK2014/000015 WO2014146663A1 (en) 2013-03-18 2014-03-17 Vaccines against chlamydia sp.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019052389A Division JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Publications (2)

Publication Number Publication Date
JP2016514713A JP2016514713A (ja) 2016-05-23
JP2016514713A5 true JP2016514713A5 (OSRAM) 2017-04-13

Family

ID=50639248

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503549A Pending JP2016514713A (ja) 2013-03-18 2014-03-17 クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン
JP2019052389A Active JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
JP2021148819A Active JP7506930B2 (ja) 2013-03-18 2021-09-13 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019052389A Active JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
JP2021148819A Active JP7506930B2 (ja) 2013-03-18 2021-09-13 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Country Status (20)

Country Link
US (4) US20140275478A1 (OSRAM)
EP (1) EP2976355B1 (OSRAM)
JP (3) JP2016514713A (OSRAM)
CN (2) CN113185587A (OSRAM)
AU (1) AU2014234765B2 (OSRAM)
BR (1) BR112015023886B1 (OSRAM)
CA (1) CA2907199C (OSRAM)
CY (1) CY1122905T1 (OSRAM)
DK (1) DK2976355T3 (OSRAM)
ES (1) ES2781579T3 (OSRAM)
HR (1) HRP20200511T1 (OSRAM)
HU (1) HUE048573T2 (OSRAM)
LT (1) LT2976355T (OSRAM)
PL (1) PL2976355T3 (OSRAM)
PT (1) PT2976355T (OSRAM)
RS (1) RS60135B1 (OSRAM)
RU (1) RU2723046C2 (OSRAM)
SI (1) SI2976355T1 (OSRAM)
SM (1) SMT202000160T1 (OSRAM)
WO (1) WO2014146663A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10688171B2 (en) 2015-02-10 2020-06-23 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
CN104800841B (zh) * 2015-03-02 2019-04-02 中国农业科学院兰州兽医研究所 牦牛流产衣原体灭活疫苗及其制备方法
EP3274716B1 (en) 2015-03-24 2019-05-08 Universiteit Gent A method and peptides for the detection of chlamydia suis
WO2017075653A1 (en) * 2015-11-04 2017-05-11 University Of The Sunshine Coast Chlamydia antigens and uses thereof
US10835601B2 (en) 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
NL2019320B1 (en) * 2017-03-02 2018-09-21 Biosparq B V Diagnostic method and system for diagnosis
CA3057318A1 (en) * 2017-03-23 2018-09-27 Ohio State Innovation Foundation Recombinant chlamydia-activated b cell platforms and methods of use thereof
RU2721123C1 (ru) * 2019-09-26 2020-05-18 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Штамм рекомбинантной псевдоаденовирусной частицы, экспрессирующий химерный ген MBL-CT666 Chlamydia trachomatis, способ его получения, иммуногенная композиция для защиты от урогенитального хламидиоза человека
CA3205280A1 (en) * 2020-12-23 2022-06-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CN116854812B (zh) * 2022-03-23 2024-09-24 东莞市朋志生物科技有限公司 抗沙眼衣原体的抗体、检测沙眼衣原体的试剂和试剂盒
CN115975049A (zh) * 2022-11-12 2023-04-18 北京成大天和生物科技有限公司 一种沙眼衣原体重组蛋白及其制备方法和应用
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
WO2025104023A1 (en) 2023-11-13 2025-05-22 Ziphius Nv MODIFIED ALPHAVIRAL nsP3

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5869608A (en) 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
EP0662083A1 (en) 1992-09-18 1995-07-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthetic peptide vaccine for chlamydia trachomatis
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
EP1812058B1 (en) * 2004-10-25 2012-06-13 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
AU2006247188A1 (en) * 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
TW201012929A (en) * 2008-09-29 2010-04-01 Univ Nat Pingtung Sci & Tech A hybridoma cell line producing monoclonal antibodies against chalmydophila aborts
AU2010207828B2 (en) * 2009-01-29 2016-07-14 British Columbia Cancer Agency Branch Compositions comprising Chlamydia antigens
US8735543B2 (en) * 2010-05-28 2014-05-27 Spixia Biotechnology Ab Chimeric MOMP antigen
ES2670095T3 (es) * 2011-06-17 2018-05-29 Universiteit Gent Vacunas contra Chlamydia

Similar Documents

Publication Publication Date Title
JP2016514713A5 (OSRAM)
JP2019163253A5 (OSRAM)
RU2015141214A (ru) Вакцины против Chlamydia sp.
Qi et al. Intranasal nanovaccine confers homo‐and hetero‐subtypic influenza protection
LeCureux et al. Lactobacillus mucosal vaccine vectors: immune responses against bacterial and viral antigens
JP2016196472A5 (OSRAM)
CN106659777A8 (zh) 免疫原性组合产品
JP2014530010A5 (OSRAM)
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
JP2011250797A5 (OSRAM)
HRP20180216T1 (hr) Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae
JP2017081939A5 (OSRAM)
JP2016506416A5 (OSRAM)
JP2013517783A5 (OSRAM)
JP2014502156A5 (OSRAM)
Yong et al. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles
Song et al. Plant‐based, adjuvant‐free, potent multivalent vaccines for avian influenza virus via Lactococcus surface display
JP2016504993A5 (OSRAM)
JP2014507146A5 (OSRAM)
HRP20180339T1 (hr) Imunogeni pripravak
JP2013518052A5 (OSRAM)
Guo et al. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection
JP2015529677A5 (OSRAM)
JP2012519724A5 (OSRAM)
JP2015521206A5 (OSRAM)